Impact News +++ Directors’ Dealings News: Rubean AG (EQS) +++ RUBEAN Aktie +3,13%

MEREO BIOPHARMA ADR Aktie

>MEREO BIO Aktienkurs

0.382 EUR +2.7% (TradegateBSX)

Ask: 0.384 EUR / 3907 Stück

Bid: 0.371 EUR / 5579 Stück

Tagesumsatz: 10250 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MEREO BIO Aktie über LYNX handeln

Intraday

1 Jahr

>MEREO BIO Performance

1 Woche: +21,3%

1 Monat: -28,0%

3 Monate: -76,2%

6 Monate: -73,9%

1 Jahr: -86,6%

laufendes Jahr: +50,4%

>MEREO BIOPHARMA ADR Aktie

Name:

MEREO BIOPHARMA ADR

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US5894921072 / A2PEYJ

Symbol/ Ticker:

MAH0 (Frankfurt) / MREO (NASDAQ)

Kürzel:

FRA:MAH0, ETR:MAH0, MAH0:GR, NASDAQ:MREO

Index:

Webseite:

https://www.mereobiopharm..

Profil:

Mereo BioPharma Group plc is structured as an American Depositary Receipt (ADR), a financial asset that provides US investors easy access to the shares of the UK-based biopharmaceutical company on Ame..
>Volltext..

Marktkapitalisierung:

50.01 Mio. EUR

Unternehmenswert:

9.18 Mio. EUR

Umsatz:

0.43 Mio. EUR

EBITDA:

-39.24 Mio. EUR

Nettogewinn:

-35.23 Mio. EUR

Gewinn je Aktie:

-0.22 EUR

Schulden:

0.34 Mio. EUR

Liquide Mittel:

41.16 Mio. EUR

Operativer Cashflow:

-27.64 Mio. EUR

Bargeldquote:

8.09

Umsatzwachstum:

-94.24%

Gewinnwachstum:

-33.35%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MEREO BIOPHARMA ADR, MEREO BIOPHARMA, MEREO BIO

Letzte Datenerhebung:

20.02.26

>MEREO BIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 159.1 Mio. St.

Frei handelbar: 87.22%

Leerverk. Aktien: 8.2%

Rückkaufquote: -0.1%

Mitarbeiter: 36

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 721.58%

Bewertung:

KGV: -

KGV lG: -

KUV: 123.3

KBV: 1.43

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 73.6%

Gewinnmarge: -8240.07%

Operative Marge: -9340.39%

Managementeffizenz:

Gesamtkaprendite: -58.57%

Eigenkaprendite: -69.98%

>MEREO BIO Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>MEREO BIO Chart & Kurs - NASDAQ

>MEREO BIO News

20.02.26 - 02:06	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO (PR Newswire)
	NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......

19.02.26 - 00:12	Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately (PR Newswire)
	Lead Plaintiff Deadline is April 6, 2026 NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) ("Mereo" or the "Company") inclusive on behalf of all persons......

18.02.26 - 15:51	NASDAQ: MREO INVESTOR ALERT: Berger Montague Advises Mereo BioPharma Group PLC (NASDAQ: MREO) Investors of an April 6, 2026 Deadline (PR Newswire)
	PHILADELPHIA, Feb. 18, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company") on behalf of investors who purchased American Depositary Shares......

17.02.26 - 02:33	MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 16, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025. A class action......

14.02.26 - 17:24	Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately (PR Newswire)
	Lead Plaintiff Deadline is April 6, 2026 NEW YORK, Feb. 14, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) ("Mereo" or the "Company") inclusive on behalf of all persons......

13.02.26 - 00:54	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO (PR Newswire)
	NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or......

12.02.26 - 21:03	Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREO (PR Newswire)
	NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO). Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......

12.02.26 - 02:27	MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025. A class action......

11.02.26 - 15:42	MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to......

09.02.26 - 09:31	MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO) for violations of §§10(b) and 20(a) of the Securities......

09.02.26 - 09:31	Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire)
	LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc ("Mereo" or "the Company") (NASDAQ: MREO ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......

07.02.26 - 12:03	MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Feb. 7, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action......

06.02.26 - 14:42	MREO Investor Alert: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to......

06.02.26 - 08:03	MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc (PR Newswire)
	SAN DIEGO, Feb. 6, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025.......

15.01.26 - 16:01	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO (PR Newswire)
	NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

14.01.26 - 15:42	Levi & Korsinsky, LLP: Ongoing Securities Investigation into Mereo BioPharma Group plc (MREO) - Contact Levi & Korsinsky (Newsfile)
	New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Mereo BioPharma Group plc ("Mereo BioPharma Group plc") (N......

06.01.26 - 12:24	XFRA: MAH0: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN MEREO BIOPH. ADR LS-,003 MAH0 US5894921072 AB/FROM ONWARDS 06.01.2026 12:13 CET...

30.12.25 - 18:15	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
	Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints....

30.12.25 - 09:03	Nasdaq Falls Over 100 Points Amid Decline In Tech Stocks: Investor Sentiment Weakens, Fear & Greed Index In ′Neutral′ Zone (Benzinga)
	U.S. stocks fell on Monday, with Nasdaq down 100 points. Nvidia Corp. and Mereo BioPharma Group plc also experienced declines. read more...

29.12.25 - 19:12	These biotech stocks are getting hammered by shocking brittle-bone treatment study results (MarketWatch)
	Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Man glaubt gar nicht, wie schwer es oft ist, eine Tat in einen Gedanken umzusetzen! - Karl Kraus

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram